
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNREp6Q1dEX3JyNTVwSlFDTU1HS3NVMUhtQkRHVXF1T1dBN2pBUEtzcEtoaHE3M0ZzWTNNZThISVBsampiQlJuSU92N25GQjFKWkZ1bktPTEMyTjVkckdkakdUZDRPbFNWZ1E4Q184R29aSUEzUWtqVjRVWnU4SS0zdkZJTlNTQU5naEp6dm9FalhJQjhrb2xxM3BwT3BNTEJRdlVsYjJXcjJSZGlxcTkxemdLQWc1dw?oc=5" target="_blank">New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
